0000000000246673

AUTHOR

Lambert Busque

showing 1 related works from this author

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escala…

2021

Although treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for the majority of patients with chronic myeloid leukemia (CML), approximately 20–30% will require a ch...

OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineText mininghemic and lymphatic diseasesInternal medicinemedicineDose escalationIn patientbusiness.industryMyeloid leukemiaHematologymedicine.diseaserespiratory tract diseases3. Good healthDasatinibOncology030220 oncology & carcinogenesisNivolumabbusinessTyrosine kinase030215 immunologyChronic myelogenous leukemiamedicine.drugLeukemia & Lymphoma
researchProduct